feed,title,long_url,short_url
Benzinga,"Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer",https://benzinga.com/general/biotech/23/01/30484626/jazz-pharma-zymeworks-highlight-84-overall-survival-at-18-months-from-zanidatamab-in-esophageal-c,https://da.gd/sj8oig
